CCTG Clinical Trials
Public Trial Select
Member Trial Select
TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancerClinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Coronavirus has an impact on clinical trial participants
Cancer clinical trials and COVID-19 (Coronavirus)
As the health care systems in Canada ramp up to meet the coming COVID-19 (Coronavirus) challenges, the Canadian Cancer Trials Group (CCTG) recognizes that this may have an impact on the conduct and availability of cancer clinical trials.
People living with cancer are at an increased risk from COVID-19 because of underlying medical conditions and a compromised immune system. Patient care, safety and well-being are a priority while we work to minimize the impact and duration of this pandemic.
Challenges for patients participating in a trial may arise from; social distancing requirements, cancer centre restrictions, travel limitations, interruptions to the supply of investigational products, or because of the strain on hospital resources. These challenges may lead to difficulties in meeting trial-specified procedures, including following trial-mandated visits or follow-up, and access to laboratory or diagnostic testing.
More >>
CCTG Annual Spring Meeting for 2020 has been cancelled
CCTG has continued to monitor the developments pertaining to the coronavirus (COVID-19).
More >>
Cell Therapy’s Promise for Canadians Must Include Access
An emerging form of immunotherapy, called adoptive cell transfer, has the potential to transform the way in which cancers are treated.
More >>
PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020
ENZAMET | CCTG PR17 (NCT02446405) study has been highlighted by the American Society of Clinical Oncology (ASCO) 2020 annual report as a major advance in cancer treatment. The results were first presented at ASCO 2019, the trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer.
More >>
An interview with Senior Investigator Annette Hay
Prof Annette Hay speaks to ecancer at the ASH 2019 meeting in Orlando about accrual barriers and detection of early toxicity signal in older, less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Prof Hay says that AML and MDS are typically diseases of older people, yet these patients are poorly represented in clinical trials.
More >>
Palliative and supportive care presentation at ESMO 2019
Approximately a fifth of patients participating in phase III breast, lung, or colorectal cancer clinical trials conducted by CCTG also used complementary medicines.
More >>
Cell Therapy’s Promise for Canadians Must Include Access
An emerging form of immunotherapy, called adoptive cell transfer, has the potential to transform the way in which cancers are treated.
More >>Planned trials
CX6
International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer SENTICOL III
HD11
Pembrolizumab and Brentuximab Vedotin versus GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma
MA40
Fulvestrant and Ipatasertib for Advanced/Metastatic HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)
PAC3
Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Recently activated
The rise of precision medicine
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
More >>
TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancer
Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.
More >>
Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide
Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.
More >>
Canadian Cancer Research Alliance announces award winners
Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham will receive the Exceptional Leadership in Patient Involvement in Cancer award.
More >>Publications
A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226
Lung Cancer 143: 1 - 11, 2020
Juergens RA;Hao D;Ellis PM;Tu D;Mates M;Kollmannsberger C;Bradbury PA;Tehfe M;Wheatley-Price P;Robinson A;Bebb G;Laskin J;Goffin J;Hilton J;Tomiak A;Hotte S;Goss GD;Brown-Walker P;Sun X;Tsao MS;Cabanero M;Gauthier I;Song X;Dennis PA;Seymour LK;Smoragiewicz M;Laurie SA;
IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia (ONLINE)
Leuk Lymphoma : 1 - 7, 2020
Assouline S;Amrein L;Aloyz R;Banerji V;Caplan S;Owen C;Hasegawa W;Robinson S;Shivakumar S;Prica A;Peters A;Hagerman L;Rodriguez L;Skamene T;Panasci L;Chen BE;Hay AE;
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies (ONLINE)
Invest New Drugs , 2020
Nehra J;Bradbury PA;Ellis PM;Laskin J;Kollmannsberger C;Hao D;Juergens RA;Goss G;Wheatley-Price P;Hotte SJ;Gelmon K;Tinker AV;Brown-Walker P;Gauthier I;Tu D;Song X;Khan A;Seymour L;Smoragiewicz M;
Joint modeling of binary response and survival for clustered data in clinical trials
Statist Med 39: 326 - 339, 2020
Chen BE;Wang J;
Optimizing whole brain radiotherapy dose and fractionation: Results from a prospective phase III trial (NCCTG N107C (Alliance)/CEC.3)
International Journal of Radiation Oncology*Biology*Physics 106: 255 - 260, 2020
Trifiletti DM;Ballman KV;Brown PD;Anderson SK;Carrero XW;Cerhan JH;Whitton AC;Greenspoon J;Parney IF;Laack NN;Ashman JB;Bahary JP;Hadjipanayis CG;Urbanic JJ;Barker FG;Farace E;Khuntia D;Giannini C;Buckner JC;Galanis E;Roberge D;
Predictive significance of an optimized immunohistochemical panel for basal-like breast cancer on the CCTG MA.12 phase III randomized clinical trial
San Antonio Breast Cancer Symposium , 2019
Asleh K;Gao D;Bramwell VH;Tu D;Shepherd LE;Nielsen TO;
Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ? Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)
Blood 134: 751 - 751, 2019
Smith M;Jegede O;Parekh S;Hanson CA;Martin P;Till BG;Crump M;Leonard JP;Friedberg JW;Kahl BS;Witzig TE;